記住我
2. Mendhiratta N, Muraki P, Sisk AE Jr, Shuch B. Papillary renal cell carcinoma: Review. Urol Oncol. 2021;39(6):327–37. 10.1016/j.urolonc.2021.04.013
3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics., 2022. CA Cancer J Clin. 2022;72(1):7–33. 10.3322/caac.21708
4. Lobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, et al. WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology. 2022;81(4):426–38. 10.1111/his.14700
5. Angori S, Lobo J, Moch H. Papillary renal cell carcinoma: Current and controversial issues. Curr Opin Urol. 2022;32(4):344–51. 10.1097/MOU.0000000000001000
6. Cornejo KM, Dong F, Zhou AG, Wu CL, Young RH, Braaten K, et al. Papillary renal cell carcinoma: Correlation of tumor grade and histologic characteristics with clinical outcome. Human Pathol. 2015;46(10):1411–7. 10.1016/j.humpath.2015.07.001
7. Sukov WR, Lohse CM, Leibovich BC, Thompson RH, Cheville JC. Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma. J Urol. 2012;187(1):54–9. 10.1016/j.juro.2011.09.053
8. Akhtar M, Al-Bozom IA, Al Hussain T. Papillary renal cell carcinoma (PRCC): An update. Adv Anat Pathol. 2019;26(2):124–32. 10.1097/PAP.0000000000000220
9. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer. 1971;28(5):1165–77. 10.1002/1097-0142(1971)28:53.0.co;2-g
10. Abou Elkassem AM, Lo SS, Gunn AJ, Shuch BM, Dewitt-Foy ME, Abouassaly R, et al. Role of imaging in renal cell carcinoma: A multidisciplinary perspective. Radiographics. 2021;41(5):1387–407. 10.1148/rg.2021200202
11. Chiarello MA, Mali RD, Kang SK. Diagnostic accuracy of MRI for detection of papillary renal cell carcinoma: A systematic and meta-analysis. AJR Am J Roentgenol. 2018;211(4), 812–21. 10.2214/AJR.17.19462
12. Srinivasan R, Hammerich K. Papillary renal cell carcinoma. In: Malouf G, Tannir N, editors. Rare kidney tumors. Cham: Springer; 2019. pp. 53–63.
13. Murugan P, Jia L, Dinatale RG, Assel M, Benfante N, Al-Ahmadie HA, et al. Papillary renal cell carcinoma: A single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. Mod Pathol. 2022;35(6):825–35. 10.1038/s41379-021-00990-9
14. Patel HD, Pierorazio PM, Johnson MH, Sharma R, Iyoha E, Allaf ME, et al. Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: A systematic review and meta-analysis. Clin J Am Soc Nephrol. 2017;12(7):1057–69. 10.2215/CJN.11941116
15. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543–52. 10.1016/j.eururo.2010.12.013
16. Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, et al. Systemic therapy for non-clear cell renal cell carcinomas: A systematic review and meta-analysis. Eur Urol. 2015;67(4), 740–9. 10.1016/j.eururo.2014.05.010
17. Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, et al. Efficacy of Savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: The SAVOIR phase 3 randomized clinical trial. JAMA Oncol. 2020;6(8):1247–55. 10.1001/jamaoncol.2020.2218
18. de Vries-Brilland M, McDermott DF, Suárez C, Powles T, Gross-Goupil M, Ravaud A, et al. Checkpoint inhibitors in metastatic papillary renal cell carcinoma. Cancer Treat Rev. 2022;99:102228. 10.1016/j.ctrv.2021.102228
19. Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: A multicentre, retrospective, cohort study. Lancet Oncol. 2019;20(4):581–90. 10.1016/S1470-2045(18)30907-0
20. Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: A randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703. 10.1016/S0140-6736(21)00152-5
21. Escudier B, Molinie V, Bracarda S, Maroto P, Szczylik C, Nathan P, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer. 2016;69:226–35. 10.1016/j.ejca.2016.08.004
22. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2016;356(22):2271–81. 10.1056/NEJMoa066838
23. Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26(2):202–9. 10.1007/s12032-009-9177-0
24. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009;15(4):1162–9. 10.1158/1078-0432.CCR-08-1229
25. Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45. 10.1056/NEJMoa1505917
26. Ledezma RA, Negron E, Paner GP, Rjepaj C, Lascano D, Haseebuddin M, et al. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol. 2016;34(5):687–93. 10.1007/s00345-015-1692-3
27. Park I, Shim YS, Go H, Hong BS, Lee JL. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures. BMC Urol. 2019;19(1):51. 10.1186/s12894-019-0484-2
28. Choi Y., Keam B., Kim M., Yoon S., Kim D., Choi J. G., et al. Bevacizumab plus Erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: A multicenter retrospective analysis in Korean patients. Cancer Res Treat. 2019;51(4):1549–56. 10.4143/crt.2019.086
29. Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Timmesfeld N, et al. Incidence and long-term prognosis of papillary renal cell carcinoma. J Cancer Res Clin Oncol. 2009;135(6):799–805. 10.1007/s00432-008-0515-y
30. Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006;107(11):2617–21. 10.1002/cncr.22340
31. Pan H, Ye L, Zhu Q, Yang Z, Hu M. The effect of the papillary renal cell carcinoma subtype on oncological outcomes. Sci Rep. 2020;10:21073. 10.1038/s41598-020-78174-9
32. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–50. 10.1038/nature13385
33. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–57. 10.1056/NEJMoa2002787
34. Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, et al. Crizotinib in patients with MET-amplified NSCLC. J Thorac Oncol. 2021;16(6):1017–29. 10.1016/j.jtho.2021.02.010
35. Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, et al. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: The SAVOIR Phase 3 randomized clinical Trial. JAMA Oncol. 2020;6(8):1247–55. 10.1001/jamaoncol.2020.2218
36. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2020;65(13):5628–37. 10.1158/0008-5472.CAN-05-0533
37. Srivastava A, Doppalapudi SK, Patel HV, Srinivasan R, Singer EA. The roaring 2020s: A new decade of systemic therapy for renal cell carcinoma. Curr Opin Oncol. 2022;34(3):234–42. 10.1097/CCO.0000000000000831
38. Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006;107(11):2617–21. 10.1002/cncr.22340
留言 (0)